DR. RALPH WEISSLEDER HONORED FOR CAREER OF SCIENTIFIC DISCOVERY IN MOLECULAR IMAGING
BEDFORD, Mass., Dec. 1 /PRNewswire/ -- The Radiologic Society of North America (RSNA) honored Ralph Weissleder, MD, PhD, with its "Outstanding Researcher of The Year" Award, recognition afforded annually to one scientist who has made original significant contributions to the field of radiology throughout a career of research. Dr. Weissleder is Professor at
"The RSNA 'Outstanding Researcher of the Year' award is an important acknowledgement of Dr. Weissleder's vision for molecular imaging as an integral component in the future of clinical medicine," said Kirtland Poss, CEO of VisEn Medical. "Dr. Weissleder's contributions have already benefited basic research and pharmaceutical development across numerous disease states, and these are increasingly advancing the era of personalized- and improved-medicine."
According to the RSNA, each "Outstanding Researcher of the Year" honoree has demonstrated a long-term commitment to radiologic research, including service as a principal investigator on peer-reviewed, nationally funded research programs, mentoring a new generation of research physicians, and leading significant scientific discoveries.
Dr. Weissleder has published over 500 peer-reviewed articles and is a founding member and past President of the Society for Molecular Imaging Research. He is the recipient of numerous scientific awards including the Allyn Taylor Prize in International Medicine, an SMI Lifetime Achievement Award and the Millennium Innovator in Medicine award.
Dr. Weissleder is also known for his significant contributions to molecular imaging research. Most of his work has been aimed at cancer, atherosclerosis and inflammatory diseases and has led to new approaches in the management of these diseases.
Dr. Weissleder is a co-founder of VisEn Medical, which has further developed and commercialized some of the leading fluorescence molecular imaging technologies originating out of Dr. Weissleder's lab at MGH, including "FMT" or fluorescent molecular tomography, as well as a portfolio of fluorescence in vivo imaging agents. The VisEn FMT 2500(TM) quantitative tomography system provides 3D quantification of disease biologies in vivo and is used by leading research institutions and pharma companies worldwide both in research and in drug development. In addition, VisEn develops and markets a broad range of fluorescent in vivo imaging agents enabling the quantification and measurement of key disease-associated biomarkers and therapeutic responses in vivo. These agents are used preclinically today, and along with the Fox Chase Cancer Center, VisEn's first "smart" fluorescence activatable agent is being planned for clinical trials in late 2009 to enable physicians to identify and characterize early stage disease in pancreatic and ovarian cancer patients.
About VisEn Medical Inc.
VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT) Imaging Systems provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific preclinical and clinical research areas.
Additional information can be found at www.visenmedical.com.
|SOURCE VisEn Medical Inc.|
Copyright©2008 PR Newswire.
All rights reserved